Resumen

Primary Objective: * Assess the efficacy of SAR443122 in cutaneous lupus erythematosus (CLE) Secondary Objectives: * Assess the effect of SAR443122 on the physician's global assessment of disease activity (PhysGA - disease activity) * Assess the effect of SAR443122 on CLE induced itch and overall pain * Assess the effect of SAR443122 on the proportion of disease activity responders compared to placebo * Assess the effect of SAR443122 on the CLASI components score * Assess the effect of SAR443122 on the Investigator's global assessment for CLE (IGA-CLE) * Assess oral cavities for patients with oral lesions * Assess the disease specific quality of life (QoL) * Assess the safety and tolerability of SAR443122 in patients with CLE * Assess the pharmacokinetics (PK) exposure of SAR443122 in patients with CLE

Descripción detallada

Total study duration per participant was up 20 weeks including: * A screening period of up to 4 weeks * A treatment period of 12 weeks * A post treatment follow-up period of 4 weeks

Elegibilidad

Edad mínima: 18 YearsEdad máxima: 80 YearsSexo: ALL

Criterios de inclusión

Participants with cutaneous lupus erythematosus either in the form of discoid/chronic cutaneous lupus erythematosus or subacute cutaneous lupus erythematosus for at least 3 months before Screening.
Participants with histologically confirmed and documented diagnosis within one year prior to Screening or during Screening period prior to randomization.
Active cutaneous lupus erythematosus skin lesions and a Cutaneous Erythematosus.
Disease Area and Severity Index activity (CLASI-A) ≥10 both at Screening and Baseline.
Participant who was candidate for systemic treatment per Investigator's judgement.

Criterios de exclusión

Systemic lupus erythematosus according to the 2012 SLICC criteria with major organ involvement.
Suspected or proven drug induced lupus erythematosus, including patients with positive antihistone autoantibody tests.
Autoimmune disease(s) other than systemic lupus erythematosus.
Active skin diseases that may interfere with the study or study assessments.
Exclusion related to tuberculosis, non-tuberculous mycobacterial infections, HIV, HBV, HCV, Herpes zoster, COVID-19 and other recurrent or recent serious infections.
Prolonged QTcF ≥ 450 ms (by Fridericia formula) or clinically significant findings on electrocardiogram (ECG).
Cannot avoid excessive UV exposure 4 weeks prior to baseline and during the study. Routine sun exposure through work are permitted but requires the use of sun block to sun exposed areas for at least 4 weeks prior to baseline and during the study.
Concomitant treatment with topical immunosuppressants beyond a stable regimen of low to medium potency topical corticosteroids and/or topical calcineurin inhibitors during the study and two weeks before baseline visit.
Initiation and/or changes in dosage of chloroquine/hydroxychloroquine within 12 weeks prior to Screening visit (or during Screening period) and/or the dose exceeding 2.3 mg/kg/day for chloroquine or 400 mg/day for hydroxychloroquine.
Systemic treatments for cutaneous or systemic lupus erythematosus or immunosuppressive therapy for autoimmune disease other than the study medication.
Systemic corticosteroids treatment \<4 weeks before baseline visit.
Live vaccine(s) within 1 month prior to Screening, or plans to receive such vaccines during the study.
Laboratory abnormalities at the Screening visit.
The above information was not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Ubicaciones

Investigational Site Number : 0320002

CABA, Buenos Aires, Argentina

Investigational Site Number : 0320003

CABA, Buenos Aires, Argentina

Investigational Site Number : 0320001

CABA, Buenos Aires, Argentina

Investigational Site Number : 0320004

Rosario, Santa Fe Province, Argentina

Investigational Site Number : 0320005

Mendoza, Argentina

Randomized, Double-blind, Placebo Controlled, Proof of Concept Study Assessing the Efficacy and Safety of the RIPK1-inhibitor SAR443122 in Patients With Moderate to Severe Subacute or Discoid/Chronic Cutaneous Lupus Erythematosus

Resumen

Descripción detallada

Elegibilidad

Criterios de inclusión

Criterios de exclusión

Intervenciones

SAR443122

Placebo

Ubicaciones

Investigational Site Number : 0320002

Investigational Site Number : 0320003

Investigational Site Number : 0320001

Investigational Site Number : 0320004

Investigational Site Number : 0320005

Patrocinadores